SCHEMBL17259342

SCHEMBL17259342

O=Cc1ccc(NC(=O)CCCc2ccc(-c3ccccc3)c(N(C(=O)O)[C@H]3CC[C@H](NC(=O)OCc4ccccc4)CC3)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.41
ALDH1A1 P00352 3/20 0.40
GAA P10253 1/20 0.40
TGM2 P21980 6/20 0.39
TSHR P16473 2/20 0.39
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
F13A1 P00488 4/20 0.38
TGM1 P22735 4/20 0.38
TRPV1 Q8NER1 1/20 0.38
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17259340 1.00 EPHX1 (0.41) EPHX1ALDH1A1GAATGM2TSHR
SCHEMBL17259425 0.83 NPC1 (0.46) ALDH1A1TSHRHDAC3HDAC4HDAC1
SCHEMBL17259423 0.83 NPC1 (0.46) ALDH1A1TSHRHDAC3HDAC4HDAC1
SCHEMBL15823047 0.82 CHEK1 (0.38) EPHX1ALDH1A1GAATSHRMEN1
SCHEMBL17259644 0.82 CHEK1 (0.38) EPHX1ALDH1A1GAATSHRMEN1
SCHEMBL17259471 0.80 HPGD (0.38) ALDH1A1HDAC1TRPV1KMT2AKDM1A
SCHEMBL17259473 0.80 HPGD (0.38) ALDH1A1HDAC1TRPV1KMT2AKDM1A
SCHEMBL15822752 0.79 CHEK1 (0.38) EPHX1ALDH1A1GAATSHRTRPV1
SCHEMBL15822756 0.79 CHEK1 (0.38) EPHX1ALDH1A1GAATSHRTRPV1
SCHEMBL15822860 0.79 CKS1B (0.37) HDAC3HDAC1HDAC2HDAC8KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9518050-B2 Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity ALMIRALL, S.A. (ES) 2016-12-13 US disclosed
US-20150329535-A1 NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY ALMIRALL, S.A. (ES) 2015-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329535-A1 NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY CHRM3, CHRM2, ADRB2 EPHX1 3419/4885ALDH1A1 2719/4885GAA 3174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.